Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 randomized double-blind placebo-controlled study of subcutaneous efgartigimod PH20 in active idiopathic inflammatory myopathy
MOH_2023-10-23_013000Phase 2Completed
- Sponsor
- argenx
- Start
- Jul 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Myopathies comparing efgartigimod PH20 SC with placebo (2 arms). Primary endpoint: Primary endpoint not reported in registry entry. Started Jul 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on MOH_2023-10-23_013000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-23_013000.